|Title||Ruthenium brachytherapy in conjunctival melanoma|
|Purpose||In 2018, ruthenium brachytherapy, a beta-emitter, was introduced at the department of ophthalmology in Leuven. With this presentation we will illustrate and review the results with ruthenium brachytherapy.|
|Methods||Case review and literature study. Ruthenium brachytherapy is applied after excision of the conjunctival melanoma, and calculated to deliver a dose of 100 Gy at 1 mm depth.|
|Results||In 4 patients (aged 10 to 82 years) with conjunctival melanoma, ruthenium brachytherapy was used as an adjuvant therapy. The application of the ruthenium plaque lasted for 6,8 or 9 hours.
Irritation and dry eye feeling was limited to he first month after application. In the limited follow-up no recurrence was seen, nor any irradiation side effect.
|Conclusion||With the introduction of ruthenium brachytherapy we have a safe therapy for the adjuvant treatment of bulbar conjunctival melanomas. A research of the literature shows that adjuvant therapy in conjunctival melanomas is important in reducing the number of recurrences, and tends to result in a better survival.|
|Conflict of interest||No|
|Details of conflicting interests||/|
|Last name||VAN RENTERGHEM|
|Department||KULeuven, dept ophthalmology|
|Department||KULeuven, dept ophthalmology - Jessa Hospital Hasselt, dept ophthalmology|
|City||Hasselt - Leuven|